Analysts’ Viewpoint on Market Scenario
Increase in the prevalence of prostate cancer and rise in demand for minimally invasive surgeries are driving the prostate cancer minimally invasive surgery market size. Minimally invasive surgery for prostate cancer is associated with several benefits, including shorter hospital stays, faster recovery, less pain, and fewer complications as compared to traditional open surgery.
R&D in minimally invasive surgery technologies is expected to augment market expansion during the forecast period. Development of new and advanced surgical technologies, such as robotics and laparoscopy, has made it possible to perform minimally invasive surgery with greater precision and accuracy. Vendors in the industry are focused on expansion of their presence in untapped regions in order to consolidate their prostate cancer minimally invasive surgery market share.
Prostate cancer is a form of cancer that begins in the gland cells of the prostate in males. Minimally invasive surgeries are widely used for the treatment of prostate cancer. These surgeries involve the use of specialized instruments and techniques to remove cancerous tissues with a minimum risk of damage to surrounding healthy tissues. Laparoscopic surgery, robotic surgery, and cryotherapy are various types of minimally invasive surgeries employed for the treatment of prostate cancer.
The COVID-19 pandemic has had a short-term negative impact on the global prostate cancer minimally invasive surgery industry. However, the industry recovered as the pandemic came under control and normal business operations resumed. During the pandemic, the measures taken to control the spread of the virus, such as lockdowns, travel restrictions, and the closure of non-essential businesses, disrupted the supply chain for surgical instruments and other medical equipment. These measures also reduced the number of elective surgeries being performed.
Demand for minimally invasive surgeries for the treatment of prostate cancer remained relatively stable due to the severity of the condition and the need for timely treatment. Numerous hospitals and clinics have implemented measures to ensure the safety of patients and staff, such as screening for COVID-19 symptoms and mandating the use of personal protective equipment.
Prostate cancer is the second-most commonly occurring cancer in men and the fourth-most common cancer overall. According to the International Agency for Research on Cancer (IARC), 1,414,259 people suffered from prostate cancer worldwide, which accounted for 7.3% of all new cancer cases. Additionally, as per statistics published by the American Society of Clinical Oncology (ASCO), the prevalence of prostate cancer is increasing globally, with an estimated 1 in 8 men being diagnosed with the disease at some point in their lives. Thus, high incidence of prostate cancer is anticipated to drive market progress in the next few years.
Governments of various countries are promoting the adoption of minimally invasive surgeries for the treatment of prostate cancer through various initiatives. These include R&D funding and financial incentives to hospitals and surgeons. These initiatives are also boosting the prostate cancer minimally invasive surgery market development.
The laparoscopic surgery procedure segment held largest share of the market in 2021. The segment is likely to maintain its dominance during the forecast period. Laparoscopic surgery is a viable treatment option for prostate cancer. It offers significant benefits to patients who are suitable for the procedure.
Laparoscopic surgery involves the use of specialized instruments and techniques to remove cancerous tissues with minimum risk of damage to surrounding healthy tissues. Laparoscopic prostatectomy facilitates the precise removal of the prostate. Patients also experience significantly less blood loss.
The robotic surgery segment is projected to grow at a significant rate during the forecast period. Robotic surgery offers several advantages over traditional open surgery and laparoscopic surgery. These benefits include higher precision and accuracy, reduced risk of complications, shorter recovery time, and less postoperative pain and discomfort.
According to the latest prostate cancer minimally invasive surgery market trends, the early-stage prostate cancer (stages I and II) segment held largest share in 2021. Minimally invasive prostate surgery can be an effective treatment option for early-stage prostate cancer. Patients who are not suitable for traditional open surgery due to their age or other health conditions can benefit from minimally invasive prostate surgery.
Early-stage prostate cancer generally grows very slowly and can take several years to show any symptoms or other health problems. Radiation therapy (external beam or brachytherapy) can also be employed for the treatment of early-stage prostate cancer. Robotic prostatectomy or laparoscopic prostatectomy is less invasive than radical prostatectomy and may shorten the recovery time of early-stage prostate cancer patients.
The hospitals end-user segment dominated the prostate cancer minimally invasive surgery market in 2021. Minimally invasive surgeries for the treatment of prostate cancer are typically performed in hospitals due to the availability of specialized equipment and trained medical staff. Minimally invasive surgeries involve the use of small incisions and specialized instruments to perform procedures, which requires a high level of skill and expertise.
Hospitals are equipped with the necessary equipment and staffed with trained medical professionals to perform minimally invasive surgeries. Rise in the number of hospitals worldwide is driving the segment. According to the American Hospital Association (AHA), the number of hospitals in the U.S. increased from 5,564 in 2017 to 6,093 in 2022.
According to the latest prostate cancer minimally invasive surgery market forecast, Europe is anticipated to hold largest share during 2022-2031. High prevalence of prostate cancer is driving the market in the region.
North America accounted for significant share in 2021. This can be ascribed to the presence of major market participants and well-established healthcare infrastructure. High incidence of prostate cancer and rise in adoption of minimally invasive surgeries are also fueling market statistics in the region. According to the American Cancer Society, around 268,490 new cases of prostate cancer were diagnosed in the U.S. in 2022.
The industry in Asia Pacific is expected to grow at a rapid pace during the forecast period. Surge in the prevalence of prostate cancer, rise in the geriatric population, and changes in lifestyle habits, such as smoking and unhealthy diet, are propelling market revenue in the region. Increase in the availability of affordable minimally invasive surgeries is also leading to market growth in Asia Pacific.
The prostate cancer minimally invasive surgery market report concludes with the company profiles section that includes key information such as company overview, financial overview, strategies, portfolio, segments, and recent developments.
Stakeholders in the industry are adopting various marketing strategies to expand their revenue share. These include educational and social media marketing that highlights the benefits of minimally invasive surgeries. Vendors are also adopting product launches, M&As, partnerships, and collaboration strategies to expand their market share.
AngioDynamics, B. Braun SE, Becton, Dickinson and Company, Ethicon Endo-Surgery, Inc. (Johnson & Johnson Services, Inc.), Intuitive Surgical, Medtronic, Olympus Corporation, Siemens Healthcare GmbH, and Teleflex Incorporated are key entities operating in the industry.
|
Attribute |
Detail |
|
Size Value in 2021 |
US$ 2.7 Bn |
|
Forecast (Value) in 2031 |
More than US$ 3.9 Bn |
|
Compound Annual Growth Rate (CAGR) |
3.6% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
It was valued at US$ 2.7 Bn in 2021.
It is projected to reach a value of more than US$ 3.9 Bn 2031.
It is anticipated to expand at a CAGR of 3.6% from 2022 to 2031.
Increase in prevalence of prostate cancer and rise in demand for minimally invasive surgeries.
The laparoscopic surgery segment accounted for more than 60.0% share in 2021.
Europe is expected to account for largest share from 2022 to 2031.
AngioDynamics, B. Braun SE, Becton, Dickinson and Company, Ethicon Endo-Surgery, Inc. (Johnson & Johnson Services, Inc.), Intuitive Surgical, Medtronic, Olympus Corporation, Siemens Healthcare GmbH, and Teleflex Incorporated.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Prostate Cancer Minimally Invasive Surgery Market
4. Market Overview
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Prostate Cancer Minimally Invasive Surgery Market Value Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Regulatory Scenario by Region/Globally
5.2. Key Industry Events
5.3. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long-term Impact)
6. Global Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast, by Procedure
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Procedure, 2017–2031
6.3.1. Laparoscopic Surgery
6.3.2. Robotic Surgery
6.3.3. Radiation Therapy
6.3.4. Cryosurgery
6.3.5. Others
6.4. Market Attractiveness Analysis, by Procedure
7. Global Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast, by Stage
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Stage, 2017–2031
7.3.1. Early-stage Prostate Cancer (Stages I and II)
7.3.2. Locally Advanced Prostate Cancer (Stage III)
7.3.3. Advanced Prostate Cancer (Stage IV)
7.4. Market Attractiveness Analysis, by Stage
8. Global Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Specialty Clinics
8.3.3. Ambulatory Surgery Centers
8.4. Market Attractiveness Analysis, by End-user
9. Global Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Procedure, 2017–2031
10.2.1. Laparoscopic Surgery
10.2.2. Robotic Surgery
10.2.3. Radiation Therapy
10.2.4. Cryosurgery
10.2.5. Others
10.3. Market Value Forecast, by Stage, 2017–2031
10.3.1. Early-stage Prostate Cancer (Stages I and II)
10.3.2. Locally Advanced Prostate Cancer (Stage III)
10.3.3. Advanced Prostate Cancer (Stage IV)
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.4.3. Ambulatory Surgery Centers
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Procedure
10.6.2. By Stage
10.6.3. By End-user
10.6.4. By Country
11. Europe Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Procedure, 2017–2031
11.2.1. Laparoscopic Surgery
11.2.2. Robotic Surgery
11.2.3. Radiation Therapy
11.2.4. Cryosurgery
11.2.5. Others
11.3. Market Value Forecast, by Stage, 2017–2031
11.3.1. Early-stage Prostate Cancer (Stages I and II)
11.3.2. Locally Advanced Prostate Cancer (Stage III)
11.3.3. Advanced Prostate Cancer (Stage IV)
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Specialty Clinics
11.4.3. Ambulatory Surgery Centers
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Procedure
11.6.2. By Stage
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Procedure, 2017–2031
12.2.1. Laparoscopic Surgery
12.2.2. Robotic Surgery
12.2.3. Radiation Therapy
12.2.4. Cryosurgery
12.2.5. Others
12.3. Market Value Forecast, by Stage, 2017–2031
12.3.1. Early-stage Prostate Cancer (Stages I and II)
12.3.2. Locally Advanced Prostate Cancer (Stage III)
12.3.3. Advanced Prostate Cancer (Stage IV)
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Specialty Clinics
12.4.3. Ambulatory Surgery Centers
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Procedure
12.6.2. By Stage
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Procedure, 2017–2031
13.2.1. Laparoscopic Surgery
13.2.2. Robotic Surgery
13.2.3. Radiation Therapy
13.2.4. Cryosurgery
13.2.5. Others
13.3. Market Value Forecast, by Stage, 2017–2031
13.3.1. Early-stage Prostate Cancer (Stages I and II)
13.3.2. Locally Advanced Prostate Cancer (Stage III)
13.3.3. Advanced Prostate Cancer (Stage IV)
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Specialty Clinics
13.4.3. Ambulatory Surgery Centers
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Procedure
13.6.2. By Stage
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Prostate Cancer Minimally Invasive Surgery Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Procedure, 2017–2031
14.2.1. Laparoscopic Surgery
14.2.2. Robotic Surgery
14.2.3. Radiation Therapy
14.2.4. Cryosurgery
14.2.5. Others
14.3. Market Value Forecast, by Stage, 2017–2031
14.3.1. Early-stage Prostate Cancer (Stages I and II)
14.3.2. Locally Advanced Prostate Cancer (Stage III)
14.3.3. Advanced Prostate Cancer (Stage IV)
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Specialty Clinics
14.4.3. Ambulatory Surgery Centers
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Procedure
14.6.2. By Stage
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2021)
15.3. Company Profiles
15.3.1. AngioDynamics
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. B. Braun SE
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Becton, Dickinson and Company
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Ethicon Endo-Surgery, Inc. (Johnson & Johnson Services, Inc.)
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Intuitive Surgical
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Medtronic
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Olympus Corporation
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Siemens Healthcare GmbH
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Teleflex Incorporated
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Product Portfolio
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
List of Tables
Table 01: Global Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by Procedure, 2017–2031
Table 02: Global Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by Stage, 2017–2031
Table 03: Global Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Global Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by Procedure, 2017–2031
Table 06: North America Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by Stage, 2017–2031
Table 07: North America Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 08: North America Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 09: Europe Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by Procedure, 2017–2031
Table 10: Europe Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by Stage, 2017–2031
Table 11: Europe Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 12: Europe Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Asia Pacific Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by Procedure, 2017–2031
Table 14: Asia Pacific Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by Stage, 2017–2031
Table 15: Asia Pacific Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 16: Asia Pacific Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Latin America Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by Procedure, 2017–2031
Table 18: Latin America Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by Stage, 2017–2031
Table 19: Latin America Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 20: Latin America Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 21: Middle East & Africa Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by Procedure, 2017–2031
Table 22: Middle East & Africa Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by Stage, 2017–2031
Table 23: Middle East & Africa Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 24: Middle East & Africa Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by Procedure, 2021 and 2031
Figure 03: Global Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by Procedure, 2022–2031
Figure 04: Global Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by Stage, 2021 and 2031
Figure 05: Global Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by Stage, 2022–2031
Figure 06: Global Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by End-user, 2021 and 2031
Figure 07: Global Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by End-user, 2022–2031
Figure 08: Global Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by Region, 2021 and 2031
Figure 09: Global Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by Region, 2022–2031
Figure 10: North America Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, 2017–2031
Figure 11: North America Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by Procedure, 2021 and 2031
Figure 12: North America Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by Procedure, 2022–2031
Figure 13: North America Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by Stage, 2021 and 2031
Figure 14: North America Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by Stage, 2022–2031
Figure 15: North America Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by End-user, 2021 and 2031
Figure 16: North America Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by End-user, 2022–2031
Figure 17: North America Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by Country, 2021 and 2031
Figure 18: North America Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by Country, 2022–2031
Figure 19: Europe Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, 2017–2031
Figure 20: Europe Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by Procedure, 2021 and 2031
Figure 21: Europe Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by Procedure, 2022–2031
Figure 22: Europe Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by Stage, 2021 and 2031
Figure 23: Europe Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by Stage, 2022–2031
Figure 24: Europe Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by End-user, 2021 and 2031
Figure 25: Europe Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by End-user, 2022–2031
Figure 26: Europe Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 27: Europe Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 28: Asia Pacific Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, 2017–2031
Figure 29: Asia Pacific Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by Procedure, 2021 and 2031
Figure 30: Asia Pacific Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by Procedure, 2022–2031
Figure 31: Asia Pacific Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by Stage 2021 and 2031
Figure 32: Asia Pacific Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by Stage, 2022–2031
Figure 33: Asia Pacific Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by End-user, 2021 and 2031
Figure 34: Asia Pacific Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by End-user, 2022–2031
Figure 35: Asia Pacific Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 36: Asia Pacific Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 37: Latin America Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, 2017–2031
Figure 38: Latin America Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by Procedure, 2021 and 2031
Figure 39: Latin America Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by Procedure, 2022–2031
Figure 40: Latin America Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by Stage, 2021 and 2031
Figure 41: Latin America Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by Stage, 2022–2031
Figure 42: Latin America Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by End-user, 2021 and 2031
Figure 43: Latin America Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by End-user, 2022–2031
Figure 44: Latin America Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 45: Latin America Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 46: Middle East & Africa Prostate Cancer Minimally Invasive Surgery Market Value (US$ Mn) Forecast, 2017–2031
Figure 47: Middle East & Africa Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by Procedure, 2021 and 2031
Figure 48: Middle East & Africa Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by Procedure, 2022–2031
Figure 49: Middle East & Africa Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by Stage, 2021 and 2031
Figure 50: Middle East & Africa Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by Stage, 2022–2031
Figure 51: Middle East & Africa Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by End-user, 2021 and 2031
Figure 52: Middle East & Africa Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by End-user, 2022–2031
Figure 53: Middle East & Africa Prostate Cancer Minimally Invasive Surgery Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 54: Middle East & Africa Prostate Cancer Minimally Invasive Surgery Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 55: Global Prostate Cancer Minimally Invasive Surgery Market Share Analysis, by Company, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Prostate Cancer Minimally Invasive Surgery Market
